LivaNova (NASDAQ:LIVN) PT Raised to $66.00

LivaNova (NASDAQ:LIVN) had its target price increased by research analysts at Robert W. Baird from $58.00 to $66.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 2.88% from the company’s previous close.

A number of other research firms also recently weighed in on LIVN. Mizuho lifted their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price target on shares of LivaNova in a report on Wednesday. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Finally, Barclays raised their target price on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded up $1.23 on Thursday, hitting $64.15. 891,504 shares of the company were exchanged, compared to its average volume of 781,875. The company’s 50 day moving average price is $54.57 and its two-hundred day moving average price is $50.94. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of -106.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.51 and a current ratio of 3.17. LivaNova has a one year low of $42.75 and a one year high of $64.36.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.45 by $0.28. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Research analysts expect that LivaNova will post 3.01 earnings per share for the current year.

Institutional Trading of LivaNova

Several institutional investors and hedge funds have recently made changes to their positions in LIVN. Handelsbanken Fonder AB grew its stake in shares of LivaNova by 100.0% during the third quarter. Handelsbanken Fonder AB now owns 17,474 shares of the company’s stock worth $924,000 after purchasing an additional 8,737 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of LivaNova by 20.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,176 shares of the company’s stock valued at $591,000 after acquiring an additional 1,923 shares during the last quarter. Strs Ohio increased its stake in shares of LivaNova by 560.0% in the 3rd quarter. Strs Ohio now owns 9,900 shares of the company’s stock valued at $523,000 after acquiring an additional 8,400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of LivaNova by 2.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,202 shares of the company’s stock valued at $1,438,000 after acquiring an additional 544 shares during the period. Finally, Emerald Advisers LLC boosted its stake in LivaNova by 5.2% during the 3rd quarter. Emerald Advisers LLC now owns 622,491 shares of the company’s stock worth $32,917,000 after acquiring an additional 30,636 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.